Novel Vaccine Approach for Cancer Immunotherapy Using Tumor Cells

Strategic Insights -

Scientists have developed a novel vaccine approach for cancer immunotherapy by engineering tumor cells to codisplay on their surface costimulatory proteins, such as 4-1BBL and LIGHT. This approach, known as ProtEx technology, involves generating immunological ligands with core streptavidin (SA) and displaying them on biotinylated cells in a rapid and efficient manner. The researchers demonstrated that tumor cells codisplaying both chimeric proteins showed 100% efficacy in a prophylactic and 55% efficacy in a therapeutic tumor setting, compared to significantly reduced efficacy when engineered with either protein alone.

Key Takeaways:

  • The researchers developed a novel vaccine approach, ProtEx technology, that involves generating immunological ligands with core streptavidin (SA) and displaying them on biotinylated cells.
  • Tumor cells engineered to codisplay on their surface two costimulatory proteins, SA-4-1BBL and SA-LIGHT, simultaneously showed 100% efficacy in a prophylactic and 55% efficacy in a therapeutic tumor setting.
  • Vaccine efficacy was associated with the generation of primary and memory T-cell and antibody responses against the tumor without detectable signs of autoimmunity.
  • The study was conducted by R.K. Sharma and colleagues at the University of Louisville, James Graham Brown Cancer Center.
  • The researchers concluded that engineering tumor cells in a rapid and effective manner to simultaneously display on their surface a collection of immunostimulatory proteins presents a novel alternative approach to gene therapy with considerable potential for cancer immunotherapy.

Statistics:

  • 100% efficacy in prophylactic tumor setting
  • 55% efficacy in therapeutic tumor setting
  • Vaccine efficacy was associated with the generation of primary and memory T-cell responses against the tumor
  • No detectable signs of autoimmunity were observed in the experiment

Sources:

  • Cancer Gene Therapy
  • Sharma, et al. (2010) "Tumor cells engineered to codisplay on their surface 4-1BBL and LIGHT costimulatory proteins as a novel vaccine approach for cancer immunotherapy."
  • University of Louisville, James Graham Brown Cancer Center, Department of Microbiology and Immunology
  • Cancer Vaccine Week editors, Cancer Vaccine Week (2010)